New drug gecacitinib offers hope for Hard-to-Treat GVHD
NCT ID NCT07476872
First seen Mar 31, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This study tests a new drug called gecacitinib in 33 adults with chronic graft-versus-host disease (cGVHD) that hasn't improved with steroids. The goal is to find a safe dose and see if it can control the disease. Participants must have had a stem cell transplant and have active cGVHD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.